• net sales from €0.8 million for the first quarter of 2023

• Cash position of €21.4 million away March 312023

April 19, 2023 – Release at 7:30am BST
Sophia Antipolis, France

Nicox S.A FR COX))), an international eye care company, today announced financial and business highlights for the first quarter of 2023 for Nicox SA and its subsidiaries (the “Nicox Group”).

ffirst Quarter 2023 Financial highlights

net sales¹ for the first quarter of 2023 was EUR 0.8 million (consisting solely of net license payments). This compares to net sales for the first quarter of 2022 of EUR 0.7 million (consisting entirely of net royalties).

As of March 31, 2023, Nicox Group had cash and cash equivalents of €21.4 million compared to €27.7 million as of December 31, 2022. The Company estimates that it will be funded through the second quarter of 2024, excluding based on NCX 470 development.

As of March 31, 2023, Nicox Group had financial debt of €22.8 million consisting of (i) €18.8 million in the form of a bond financing agreement signed in January 2019 with Kreos Capital, (ii) a loan of €1 €.7 million agreement guaranteed by the French State and granted in August 2020 in connection with the COVID-19 pandemic and (iii) €2.3 million cash value attributed to the put option² granted in the November 2022 equity financing. Payment of this debt would only occur if the put option were exercised, subject to the conditions set forth in footnote 2 below.

VYZULTA^® (Latanoprosten-Bunod ophthalmic solution), 0.024% US prescriptions³ increased 23% in the first quarter of 2023 compared to the same period in 2022. VYZULTA, licensed exclusively to Bausch + Lomb worldwide, is marketed in more than 15 countries including the US and is also approved in a number of other countries. VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

company update

• Nicox’s exclusive Chinese licensing partner, Ocumension…